Insider buying last 90 days
No open-market insider purchases were filed for SMMT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Summit Therapeutics moved higher this week after third-quarter results showed a narrower net loss of $208.4 million, or adjusted loss per share of $(0.20), beating analyst estimates of $(0.28). The quarter also featured a nine-month net loss of $613.5 million, shareholder approval to raise authorized common stock to 2 billion shares, and confirmation that AstraZeneca invested $2 billion in the company. Stifel lowered its price target to $37 from $38 while maintaining a Buy rating, citing valuation concerns even as it highlighted promising ivonescimab data and accelerated enrollment in colorectal cancer trials.
Shares closed at $17.84, up 9.2% on the day, sitting above both the 50-day ($16.33) and 200-day ($16.15) moving averages, with the shorter average above the longer one. The GekkoIndex reads 52.5, placing SMMT in the Neutral zone, down 7.9 over the past five readings. Price remains 11.1% below Gekko Fair Value of $20.06.
The next earnings date falls on 22 February 2027, 99 days away, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows, though one trailblazer holder is noted. Seasonality from this point in the calendar has averaged a 25.6% move over the next 20 trading days across 5 years, rising in 3 of them. Analyst consensus among 14 firms stands at 8 buy and 6 hold ratings, with a consensus target of $30.26.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Summit Therapeutics scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $14.15 sits between the 50-day ($16.41) and 200-day ($16.15) averages, or the averages disagree.
See the chart61.7, Accumulation
Reading 61.7 is in the Accumulation zone.
See the GekkoIndex27.9% below
Price is 27.9% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 99 days
Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.
See earnings+53.7% on average
From this point in the calendar, the next 20 trading days averaged +53.7% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Summit Therapeutics closed at $14.15 on Nov 13, 2026, −24.9% over the past year, inside a 52-week range of $12.07 to $29.23.
Use the left and right arrow keys to read daily values.
Put SMMT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Summit Therapeutics works in biopharmaceutical research, focused on finding, developing, and bringing to market treatments for infectious diseases in the United States and Latin America. Much of its pipeline centers on Clostridioides difficile infection, or CDI, with an oral small-molecule antibiotic called ridinilazole as its most advanced candidate, now in Phase III trials for that condition.
Alongside ridinilazole, the company is advancing SMT-738, aimed at multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and a group of compounds known as DDS-04, which target various infections caused by Enterobacteriaceae bacteria. Its work is organized around this pipeline of infectious-disease therapies rather than a marketed product line.
Summit Therapeutics was founded in 2003 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker SMMT.
Summit Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.7, in the Accumulation zone, up 4 points over five sessions.
Up 4 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +25.7% | +36.3% | ||
| Accumulation (current zone) | 242 | +2.7% | +5.9% | ||
| Neutral | 410 | +1.7% | +8.1% | ||
| Distribution | 27 | −4.9% | −12.9% | ||
| Selling | 4 | Too few readings yet | |||
Average SMMT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Summit Therapeutics trades 27.9% below Gekko Fair Value of $19.63, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Summit Therapeutics shares are worth, recalculated every trading day.
$19.63
Gekko Fair Value, Nov 14, 2026
27.9% Undervalued
At the end of Aug 2026 the price was 41.9% below the estimate.
No open-market insider purchases were filed for Summit Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for SMMT in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in SMMT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1signal, 64% of the flagged premium in calls.
Latest: Bullish flow on Nov 14, $746K in unusual premium.
1of the funds Gekko tracks holds SMMT.
Summit Therapeutics reports on Feb 22, 2027 (99 days away), and beat the EPS estimate in 2 of its last 8 reports.
Feb 22, 2027
99 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | −$0.28 est −$0.26 | — est $114K | −7.3% |
| Apr 30, 2026 | −$0.18 est −$0.12 | — est $54K | −22.7% |
| Feb 23, 2026 | −$0.29 est −$0.10 | — est $56.78M | +1.1% |
| Oct 20, 2025 | −$0.23 est −$0.10 | — est $76.50M | −10.7% |
| Aug 11, 2025 | −$0.76 est −$0.09 | — | −10.4% |
| May 1, 2025 | −$0.07 est −$0.07 | — | +15.7% |
| Feb 24, 2025 | −$0.07 est −$0.08 | — | −18.1% |
| Oct 30, 2024 | −$0.08 est −$0.07 | — | −14.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Summit Therapeutics is $29.49, +108.4% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | Wells Fargo | $30 | +112.0% |
| Nov 9 | Bernstein | $11.90 | −15.9% |
| Nov 5 | Evercore ISI | $34 | +140.3% |
| Nov 5 | H.C. Wainwright | — | — |
| Nov 5 | Stifel Nicolaus | $37 | +161.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Summit Therapeutics averaged +53.7% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −6.0% | 1 of 5 |
| Next 10 trading days | −5.1% | 0 of 5 |
| Next 15 trading days | +27.5% | 4 of 5 |
| Next 20 trading days | +53.7% | 2 of 5 |
| Next 30 trading days | +68.9% | 2 of 5 |
For scale, SMMT’s typical 20-trading-day move in either direction is about 14.5%.
Summit Therapeutics’s market cap is $11.29B and revenue of $0 over the last twelve months.
Coverage of Summit Therapeutics this week reads negative: 0 positive, 1 neutral and 3 negative headlines.
Summit Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Summit Therapeutics’s market cap is $11.29B at the Nov 13, 2026 close of $14.15, with 799.8M shares outstanding.
The consensus analyst 12-month price target for Summit Therapeutics is $29.49, +108.4% from the last close. Of the 14 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Summit Therapeutics is undervalued: the Nov 13, 2026 close of $14.15 is 27.9% below Gekko Fair Value of $19.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Summit Therapeutics is expected to report on Feb 22, 2027 (99 days away). Analysts expect earnings of −$0.36 per share on revenue of $3.01M. Summit Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 12.6% on average across the report.
Summit Therapeutics’s 52-week high is $29.23 and its 52-week low is $12.07; it closed at $14.15 on Nov 13, 2026, −24.9% over the past year. Over the last five years the shares peaked at $36.91 on Apr 24, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Summit Therapeutics over the last 30 days, with $477K of flagged premium in calls and $269K in puts. The latest, bullish flow, was on Nov 14, 2026 with $746K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.